1. Emerging Considerations in the Use of Immune Checkpoint Inhibitors: What Is MSI?

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. NCCN Guidelines for Treatment of dMMR/MSI-H CRC

5. Background on MMR and MSI

6. Pathways to Mismatch Repair Deficiency in CRC

7. Testing Methodologies for dMMR/MSI

8. Testing Algorithm for MSI

9. Purpose of MSI Testing: Historical vs Current

10. Rate Across Solid Tumor Types

11. Relationship of MSI to Immunologic Response

12. Phase 2 Study of Pembrolizumab on dMMR or pMMR Metastatic Carcinomas

13. Phase 2 Study of Pembrolizumab on Different dMMR Tumor Types

14. Phase 2 Study of Nivolumab Monotherapy in dMMR/MSI-H mCRC: CheckMate 142

15. PFS and OS in CheckMate 142 Study

16. Phase 2 Study of Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC: CheckMate 142

17. Toxicity of Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC: CheckMate 142

18. Phase 1b Study of Atezolizumab Plus Bevacizumab in MSI-H CRC

19. Chemotherapy Plus Immunotherapy for MSI-H mCRC

20. MSI-H Tumors Are Heterogeneous

21. NCCN Guidelines for dMMR/MSI-H Testing

22. Faculty Suggestions for MSI Testing

23. Targeted Agents Plus Immunotherapy for MSS Tumors

24. Atezolizumab ± Cobimetinib vs Regorafenib in MSS CRC: COTEZO IMblaze370

25. Discussion on Overcoming Therapeutic Resistance

26. New Therapeutic Approaches

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)

30. Abbreviations (cont)

31. Abbreviations (cont)